English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Small molecule inhibitors of mammalian glycosylation

MPS-Authors
/persons/resource/persons293239

Almahayni,  Karim
International Max Planck Research School, Max Planck Institute for the Science of Light, Max Planck Society;
Möckl Research Group, Research Groups, Max Planck Institute for the Science of Light, Max Planck Society;
Friedrich-Alexander Universität Erlangen-Nürnberg;

/persons/resource/persons293241

Spiekermann,  Malte
Möckl Research Group, Research Groups, Max Planck Institute for the Science of Light, Max Planck Society;
Friedrich-Alexander Universität Erlangen-Nürnberg;

/persons/resource/persons252559

Möckl,  Leonhard
Möckl Research Group, Research Groups, Max Planck Institute for the Science of Light, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

1-s2.0-S2590028522000084-main.pdf
(Publisher version), 4MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Almahayni, K., Spiekermann, M., Fiore, A., Yu, G., Pedram, K., & Möckl, L. (2022). Small molecule inhibitors of mammalian glycosylation. Matrix Biology Plus, 16: 100108. doi:10.1016/j.mbplus.2022.100108.


Cite as: https://hdl.handle.net/21.11116/0000-000D-D913-9
Abstract
Glycans are one of the fundamental biopolymers encountered in living systems. Compared to polynucleotide and polypeptide biosynthesis, polysaccharide biosynthesis is a uniquely combinatorial process to which interdependent enzymes with seemingly broad specificities contribute. The resulting intracellular, cell surface, and secreted glycans play key roles in health and disease, from embryogenesis to cancer progression. The study and modulation of glycans in cell and organismal biology is aided by small molecule inhibitors of the enzymes involved in glycan biosynthesis. In this review, we survey the arsenal of currently available inhibitors, focusing on agents which have been independently validated in diverse
systems. We highlight the utility of these inhibitors and drawbacks to their use, emphasizing the need for innovation for basic research as well as for therapeutic applications.